PTN
Palatin Technologies, Inc. · AMEX
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website alatin.com
- Employees(FY) 34
- ISIN US6960775020
Performance
-5.8%
1W
-2.5%
1M
+20.37%
3M
-40.91%
6M
-51.01%
YTD
-8.88%
1Y
Profile
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
Technical Analysis of PTN 2024-05-31
Overview:
In analyzing the technical indicators for PTN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive assessment of the stock's potential price movement. By examining these key factors, we aim to offer valuable insights and predictions for the next few days.
Trend Analy...
Recent News & Updates
- 2023-05-09 05:45
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates(Yahoo Finance)
- 2023-05-08 19:30
- 2023-05-08 04:04
- 2023-05-01 04:00
Palatin Technologies to Host Key Opinion Leader Webinar(Yahoo Finance)
- 2023-04-26 19:30
- 2023-04-24 19:30
- 2023-04-18 19:30
- 2023-04-17 19:30
- 2023-03-01 18:30
- 2023-02-27 18:30
- 2023-02-14 18:30
- 2023-02-09 18:30
- 2023-01-26 04:45
- 2023-01-18 18:30
- 2023-01-17 18:30
Palatin Receives $4.7 Million of Non-Dilutive Funding(Yahoo Finance)
- 2023-01-09 18:30
- 2023-01-04 18:30
- 2022-11-13 19:55
- 2022-11-13 18:30
- 2022-11-09 19:55
- 2022-11-09 05:45
- 2022-11-09 04:16
- 2022-11-08 06:25
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates(Yahoo Finance)
- 2022-11-07 04:15
- 2022-10-30 21:30
Palatin Announces $10 Million Registered Direct Offering(Yahoo Finance)
- 2022-10-26 19:05
Swedish Orphan Biovitrum (BIOVF) Beats Q3 Earnings Estimates(Yahoo Finance)
- 2022-10-24 05:32
- 2022-10-19 19:30
- 2022-10-16 19:30
- 2022-10-12 19:30